Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi^® (Lisocabtagene Maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol Myers Squibb announced topline results from TRANSCEND CLL 004, a Phase I/II, open-label, single-arm, multicenter study evaluating Breyanzi in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.